Spleen tyrosine kinase: An Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases

Autoimmunity

Volumn 43, Issue 1, 2010, Pages 48-55

  Ghosh, Debjani ^a   Tsokos, George C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Autoimmunity; Inflammation; Kinases

Indexed keywords

FC RECEPTOR; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE;

ARTHRITIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BASOPHIL DEGRANULATION; HUMAN; INFLAMMATORY DISEASE; MAST CELL DEGRANULATION; OSTEOCLAST; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

B-LYMPHOCYTES; CELL DEGRANULATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAST CELLS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 75749123824     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916930903374717     Document Type: Review

References (76)

1. Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem 2001;130: 177-186.
2. Taniguchi T, Kobayashi T, Kondo J, Takahashi K, Nakamura H, Suzuki J, Nagai K, Yamada T, Nakamura S, Yamamura H. Molecular cloning of a porcine gene syk that encodes a 72-kDa protein-tyrosine kinase showing high susceptibility to proteolysis. J Biol Chem 1991;266: 15790-15796.
3. Sakai K, Tanaka Y, Asahi M, Shimomura R, Taniguchi T, Hashimoto E, Yamamura H. Identification of the phosphorylation sites of H2B histone by a catalytic fragment of p72syk from porcine spleen. FEBS Lett 1991;294:104-108.
4. Qiu Y, Kung HJ. Signaling network of the Btk family kinases. Oncogene 2000;19:5651-5661.
5. Muljo SA, Schlissel MS. Pre-B and pre-T-cell receptors: Conservation of strategies in regulating early lymphocyte development. Immunol Rev 2000;175:80-93.
6. Futterer K, Wong J, Grucza RA, Chan AC, Waksman G. Structural basis for Syk tyrosine kinase ubiquity in signal transduction pathways revealed by the crystal structure of its regulatory SH2 domains bound to a dually phosphorylated ITAM peptide. J Mol Biol 1998;281:523-537.
7. Hatada MH, Lu X, Laird ER, Green J, Morgenstern JP, Lou M, Marr CS, Phillips TB, Ram MK, Theriault K, Zoller MJ and Karas JL. Molecular basis for interaction of the protein tyrosine kinase ZAP-70 with the T-cell receptor. Nature 1995;377:32-38.
8. Au-Yeung BB, Deindl S, Hsu LY, Palacios EH, Levin SE, Kuriyan J, Weiss A. The structure, regulation, and function of ZAP-70. Immunol Rev 2009;228:41-57.
9. Kurosaki T. Functional dissection of BCR signaling pathways. Curr Opin Immunol 2000;12:276-281.
10. Kurosaki T, Takata M, Yamanashi Y, Inazu T, Taniguchi T, Yamamoto T, Yamamura H. Syk activation by the Src-family tyrosine kinase in the B cell receptor signaling. J Exp Med 1994;179:1725-1729.
11. Gold MR, Law DA, DeFranco AL. Stimulation of protein tyrosine phosphorylation by the B-lymphocyte antigen receptor. Nature 1990;345:810-813.
12. Hong JJ, Yankee TM, Harrison ML, Geahlen RL. Regulation of signaling in B cells through the phosphorylation of Syk on linker region tyrosines. A mechanism for negative signaling by the Lyn tyrosine kinase. J Biol Chem 2002;277:31703-31714.
13. Cambier JC. Antigen and Fc receptor signaling. The awesome power of the immunoreceptor tyrosine-based activation motif (ITAM). J Immunol 1995;155:3281-3285.
14. Depoil D, Weber M, Treanor B, Fleire SJ, Carrasco YR, Harwood NE, Batista FD. Early events of B cell activation by antigen. Sci Signal 2009;2:pt1.
15. Jun JE, Goodnow CC. Scaffolding of antigen receptors for immunogenic versus tolerogenic signaling. Nat Immunol 2003;4:1057-1064.
16. Healy JI, Dolmetsch RE, Timmerman LA, Cyster JG, Thomas ML, Crabtree GR, Lewis RS, Goodnow CC. Different nuclear signals are activated by the B cell receptor during positive versus negative signaling. Immunity 1997;6: 419-428.
17. Palacios EH,Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23:7990-8000.
18. van Oers NS. T cell receptor-mediated signs and signals governing T cell development. Semin Immunol 1999;11: 227-237.
19. van Leeuwen JE, Samelson LE. T cell antigen-receptor signal transduction. Curr Opin Immunol 1999;11:242-248.
20. Chu P, Pardo J, Zhao H, Li CC, Pali E, Shen MM, Qu K, Yu SX, Huang BC, Yu P, Masuda ES, Molineaux SM, Kolbinger F, Aversa G, de Vries J, Payan DG, Liao XC. Systematic identification of regulatory proteins critical for T-cell activation. J Biol 2003;2:21.
21. Krishnan S,Warke VG, NambiarMP, Tsokos GC, Farber DL. The FcR gamma subunit and Syk kinase replace the CD3 zetachain and ZAP-70 kinase in the TCR signaling complex of human effector CD4 T cells. J Immunol 2003;170: 4189-4195.
22. Lin J, Weiss A. T cell receptor signalling. J Cell Sci 2001;114: 243-244.
23. Kadlecek TA, van Oers NS, Lefrancois L, Olson S, Finlay D, Chu DH, Connolly K, Killeen N, Weiss A. Differential requirements for ZAP-70 in TCR signaling and T cell development. J Immunol 1998;161:4688-4694.
24. Arpaia E, Shahar M, Dadi H, Cohen A, Roifman CM. Defective T cell receptor signaling and CD8 + thymic selection in humans lacking zap-70 kinase. Cell 1994;76: 947-958.
25. Chan AC, Kadlecek TA, Elder ME, Filipovich AH, Kuo WL, Iwashima M, Parslow TG, Weiss A. ZAP-70 deficiency in an autosomal recessive form of severe combined immunodeficiency. Science 1994;264:1599-1601. (Pubitemid 24227717)
26. Zhang W, Sloan-Lancaster J, Kitchen J, Trible RP, Samelson LE. LAT: The ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell 1998;92: 83-92.
27. Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, Furlong MT, Geahlen RL, Tybulewicz VL. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995;378:298-302.
28. Cheng AM, Rowley B, PaoW, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B-cell development. Nature 1995;378:303-306.
29. Cheng AM, Chan AC. Protein tyrosine kinases in thymocyte development. Curr Opin Immunol 1997;9:528-533.
30. Gilbert C, Barat C, Cantin R, Tremblay MJ. Involvement of Src and Syk tyrosine kinases in HIV-1 transfer from dendritic cells to CD4+T lymphocytes. J Immunol 2007;178: 2862-2871.
31. Martelli MP, Lin H, Zhang W, Samelson LE, Bierer BE. Signaling via LAT (linker for T-cell activation) and Syk/ZAP70 is required for ERK activation and NFAT transcriptional activation following CD2 stimulation. Blood 2000;96: 2181-2190.
32. Kirshenbaum AS, Kessler SW, Goff JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+bone marrow progenitor cells. J Immunol 1991;146: 1410-1415.
33. Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature 2008;454:445-454.
34. Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev 2009;228:149-169.
35. Sada K, Zhang J, Siraganian RP. Point mutation of a tyrosine in the linker region of Syk results in a gain of function. J Immunol 2000;164:338-344.
36. Meng W, Sawasdikosol S, Burakoff SJ, Eck MJ. Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature 1999;398:84-90.
37. Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A. Functional and physical interactions of Syk family kinaseswith theVav proto-oncogene product. Immunity 1996;5: 591-604.
38. Zhang J, Siraganian RP. CD45 is essential for Fc epsilon RI signaling by ZAP70, but not Syk, in Syk-negative mast cells. J Immunol 1999;163:2508-2516.
39. Siraganian RP, Zhang J, Suzuki K, Sada K. Protein tyrosine kinase Syk in mast cell signaling. Mol Immunol 2002;38: 1229-1233.
40. Benhamou M, Siraganian RP. Protein-tyrosine phosphorylation: An essential component of Fc epsilon RI signaling. Immunol Today 1992;13:195-197.
41. ZouW, Kitaura H, Reeve J, Long F, Tybulewicz VL, Shattil SJ, Ginsberg MH, Ross FP, Teitelbaum SL. Syk, c-Src, the alphavbeta3 integrin, and ITAM immunoreceptors, in concert, regulate osteoclastic bone resorption. J Cell Biol 2007; 176:877-888.
42. Faccio R, Zou W, Colaianni G, Teitelbaum SL, Ross FP. High dose M-CSF partially rescues the Dap122/2 osteoclast phenotype. J Cell Biochem 2003;90:871-883.
43. Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 2004;428:758-763.
44. Desaulniers P, Fernandes M, Gilbert C, Bourgoin SG, Naccache PH. Crystal-induced neutrophil activation. VII. Involvement of Syk in the responses to monosodium urate crystals. J Leukoc Biol 2001;70:659-668.
45. CrowleyMT, Costello PS, Fitzer-Attas CJ, Turner M,Meng F, Lowell C, Tybulewicz VL, DeFranco AL. A critical role for Syk in signal transduction and phagocytosis mediated by Fcgamma receptors on macrophages. J ExpMed 1997;186:1027-1039.
46. Barabe F, Gilbert C, Liao N, Bourgoin SG, Naccache PH. Crystal-induced neutrophil activation VI. Involvement of FcgammaRIIIB (CD16) and CD11b in response to inflammatory microcrystals. FASEB J 1998;12:209-220.
47. Ryckman C, Gilbert C, de Medicis R, Lussier A, Vandal K, Tessier PA. Monosodium urate monohydrate crystals induce the release of the proinflammatory protein S100A8/A9 from neutrophils. J Leukoc Biol 2004;76:433-440.
48. Kiefer F, Brumell J, Al-AlawiN, Latour S, Cheng A, Veillette A, Grinstein S, Pawson T. The Syk protein tyrosine kinase is essential for Fcgamma receptor signaling in macrophages and neutrophils. Mol Cell Biol 1998;18:4209-4220.
49. Ng G, Sharma K, Ward SM, Desrosiers MD, Stephens LA, Schoel WM, Li T, Lowell CA, Ling CC, Amrein MW, Shi Y. Receptor-independent, direct membrane binding leads to cell-surface lipid sorting and Syk kinase activation in dendritic cells. Immunity 2008;29:807-818.
50. Bhagwat SS. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal 2009;5: 107-115.
51. Masuda ES, Schmitz J. Syk inhibitors as treatment for allergic rhinitis. Pulm Pharmacol Ther 2008;21:461-467.
52. Lai JY, Cox PJ, Patel R, Sadiq S, Aldous DJ, Thurairatnam S, Smith K, Wheeler D, Jagpal S, Parveen S, Fenton G, Harrison TK, McCarthy C, Bamborough P. Potent small molecule inhibitors of spleen tyrosine kinase (Syk). Bioorg Med Chem Lett 2003;13:3111-3114.
53. Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, Nakashima K, IshimoriM, Nagai H, Li YF, Yura T, Bacon KB. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5- ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigeninduced airway inflammation in rodents. J Pharmacol Exp Ther 2003;306:1174-1181.
54. Bhavaraju K, Kim S, Daniel JL, Kunapuli SP. Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5- sulfonamide] (OXSI-2), as a Syk-selective inhibitor in platelets. Eur J Pharmacol 2008;580:285-290.
55. Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther 2006;319:998-1008.
56. Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, Firestein GS. A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006;317:571-578.
57. Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007;124:244-257.
58. Rossi AB, Herlaar E, Braselmann S, Huynh S, Taylor V, Frances R, Issakani SD, Argade A, Singh R, Payan DG, Masuda ES. Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J Allergy Clin Immunol 2006;118: 749-755.
59. Yamamoto N, Hasegawa H, Seki H, Ziegelbauer K, Yasuda T. Development of a high-throughput fluoroimmunoassay for Syk kinase and Syk kinase inhibitors. Anal Biochem 2003;315: 256-261.
60. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277.
61. Tsokos GC, Liossis SN. Immune cell signaling defects in lupus: Activation, anergy and death. Immunol Today 1999;20: 119-124.
62. Alvarado-de la Barrera C, Alcocer-Varela J, Richaud-Patin Y, Alarcon-Segovia D, Llorente L. Differential oncogene and TNF-alpha mRNA expression in bone marrow cells from systemic lupus erythematosus patients. Scand J Immunol 1998;48:551-556.
63. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, Sanz I. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-3590.
64. Inaoki M, Sato S, Weintraub BC, Goodnow CC, Tedder TF. CD19-regulated signaling thresholds control peripheral tolerance and autoantibody production in B lymphocytes. J Exp Med 1997;186:1923-1931.
65. Sato S, Hasegawa M, Fujimoto M, Tedder TF, Takehara K. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J Immunol 2000;165:6635-6643.
66. Fujimoto M, Fujimoto Y, Poe JC, Jansen PJ, Lowell CA, DeFranco AL, Tedder TF. CD19 regulates Src family protein tyrosine kinase activation in B lymphocytes through processive amplification. Immunity 2000;13:47-57.
67. Tenbrock K, Juang YT, Kyttaris VC, Tsokos GC. Altered signal transduction in SLE T cells. Rheumatology (Oxford) 2007;46:1525-1530.
68. Irving BA, Chan AC,Weiss A. Functional characterization of a signal transducing motif present in the T cell antigen receptor zeta chain. J Exp Med 1993;177:1093-1103.
69. Rellahan BL, Jensen JP, Howcroft TK, Singer DS, Bonvini E, Weissman AM. Elf-1 regulates basal expression from the T cell antigen receptor zeta-chain gene promoter. J Immunol 1998; 160:2794-2801.
70. Juang YT, Tenbrock K, Nambiar MP, Gourley MF, Tsokos GC. Defective production of functional 98-kDa form of Elf-1 is responsible for the decreased expression of TCR zeta-chain in patients with systemic lupus erythematosus. J Immunol 2002;169:6048-6055.
71. Enyedy EJ, NambiarMP, Liossis SN, Dennis G, Kammer GM, Tsokos GC. Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum 2001;44: 1114-1121.
72. Tsokos GC, Nambiar MP, Tenbrock K, Juang YT. Rewiring the T-cell: Signaling defects and novel prospects for the treatment of SLE. Trends Immunol 2003;24:259-263.
73. Krishnan S, Nambiar MP, Warke VG, Fisher CU, Mitchell J, DelaneyN,TsokosGC. Alterations in lipid raft composition and dynamics contribute to abnormal T cell responses in systemic lupus erythematosus. J Immunol 2004;172:7821-7831.
74. Deng GM, Tsokos GC. Cholera toxin B accelerates disease progression in lupus-prone mice by promoting lipid raft aggregation. J Immunol 2008;181:4019-4026.
75. Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008;58:1433-1434.
76. Weinblatt ME, Kavanaugh A, Grossbard E. Presentation: Treatment of rheumatoid arthritis (RA) with a Syk kinase inhibitor: A 12 week randomized placebo controlled study Annual Scientific Meeting by American College of Rheumatology. Abstract no 1189, 2008.